The Palatability of Lopinavir and Ritonavir Delivered by an Innovative Freeze-Dried Fast-Dissolving Tablet Formulation

The Palatability of Lopinavir and Ritonavir Delivered by an Innovative Freeze-Dried Fast-Dissolving Tablet Formulation

Negative hedonic sensory qualities of HIV antiretroviral drugs often reduce patient adherence particularly in pediatric populations requiring oral consumption. This study examines the palatability of an innovative delivery mechanism utilizing a freeze-drying-in-blister approach to create fast-dissol...

Full description

Bibliographic Details
Main Authors:	David W. Pittman, Alexandra M. Brantly, Alexandra L. Drobonick, Hannah T. King, Daniel C. Mesta, Caroline G. Richards, Manjari Lal, Manshun Lai
Format:	Article
Language:	English
Published:	Hindawi Limited 2018-01-01
Series:	AIDS Research and Treatment
Online Access:	http://dx.doi.org/10.1155/2018/5908167

Similar Items

Recurrent oedema associated with the co-formulation of lopinavir and ritonavir Edema recorrente associado à co-formulação de lopinavir e ritonavir
by: Jorge Francisco C. Pinto, et al.
Published: (2004-08-01)

Toxicity for warfarine switching from lopinavir/ritonavir to dolutegravir
by: Ana Pelufo-Pellicer, et al.
Published: (2017-03-01)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
by: Farinotti Robert, et al.
Published: (2010-05-01)

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Esma Eroğlu, et al.
Published: (2020-12-01)

Lopinavir/ritonavir for COVID-19: A living systematic review
by: Francisca Verdugo-Paiva, et al.
Published: (2020-07-01)

Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir).
by: Kathleen M S E Reyskens, et al.
Published: (2013-01-01)

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
by: Ashish Chandwani, et al.
Published: (2008-09-01)

Stavudine-induced pancreatitis followed by lopinavir-ritonavir-induced pancreatitis
by: Anand H, et al.
Published: (2008-01-01)

Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir
by: Paula Mazan, et al.
Published: (2020-05-01)

355 Lopinavir/ritonavir treatment in paediatric patients with covid-19
by: P Ip, et al.
Published: (2021-04-01)

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Şule Özdemir, et al.
Published: (2020-12-01)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
by: Kathleen M. S. E. Reyskens, et al.
Published: (2013-01-01)

Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer
by: Rahaba Marima, et al.
Published: (2020-08-01)

Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
by: Adewale Bayode Owa, et al.
Published: (2020-10-01)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir).
by: Kathleen M. S. E. Reyskens, et al.
Published: (2013-01-01)

HPTLC Method for Simultaneous Determination of Lopinavir and Ritonavir in Capsule Dosage Form
by: A. V. Sulebhavikar, et al.
Published: (2008-01-01)

Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children
by: Beatriz Larru Martinez, et al.
Published: (2010-03-01)

Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavir initiation
by: Wilhelm P. Greffrath, et al.
Published: (2018-06-01)

The maladaptive effects of HIV protease inhibitors (Lopinavir/Ritonavir) on the rat heart.
by: Reyskens, Kathleen Maria Simone Elise
Published: (2013)

Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis
by: Bahman Amani, et al.
Published: (2021-05-01)

Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials
by: Tejas K. Patel, et al.
Published: (2021-06-01)

Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities
by: Mario Ferreira Peixoto, M.D., et al.
Published: (2011-05-01)

Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir
by: Tatsuhiko Wada, et al.
Published: (2020-05-01)

Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients
by: D. Zanon, et al.
Published: (2020-12-01)

Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities
by: Mario Ferreira Peixoto, et al.

USE OF LOPINAVIR/RITONAVIR ASSOCIATED WITH ERGOTAMINE RESULTING IN FOOT AMPUTATION: BRIEF COMMUNICATION
by: Fernando Raphael de Almeida Ferry, et al.
Published: (2014-06-01)

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment
by: Paola Magro, et al.
Published: (2021-03-01)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
by: Nicola Gianotti, et al.
Published: (2017-01-01)

Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy in Patients With COVID-19
by: Yannick Binois, et al.
Published: (2020-10-01)

Stavudine-induced pancreatitis followed by lopinavir-ritonavir-induced pancreatitis: Is co-trimoxazole the culprit?
by: Bhargava P
Published: (2008-01-01)

Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir
by: Christiana Smith, et al.
Published: (2016-01-01)

Simultaneous determination of plasma lopinavir and ritonavir by chemometrics-assisted spectrophotometry and comparison with HPLC method
by: Chutima Matayatsuk Phechkrajang
Published: (2013-06-01)

Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.
by: Richard A Murphy, et al.
Published: (2012-01-01)

The effects of HIV Protease Inhibitors (Lopinavir/Ritonavir) on the non-oxidative pathways of glucose metabolism
by: Fisher, Tarryn-Lee
Published: (2014)

Comparison of non-severe COVID-19 pneumonia patients treated with lopinavir/ritonavir and favipiravir
by: Bengü Şaylan, et al.
Published: (2020-11-01)

Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients.
by: Johanna Schneider, et al.
Published: (2021-01-01)

Dyslipidaemia associated with the highly active antiretroviral therapy in aids patient: reversion after switching (stavudine to tenofovir and lopinavir/ritonavir to atazanavir/ritonavir)
by: Hamilton Domingos, et al.

Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules
by: Parekh Paras, et al.
Published: (2008-09-01)

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
by: Timothy P. Sheahan, et al.
Published: (2020-01-01)

The Effectiveness of Hydroxychloroquine Versus Hydroxychloroquine Plus Lopinavir/Ritonavir Therapy in SARSCoV- 2 Pneumonia
by: Ayşe BATIREL, et al.
Published: (2021-12-01)

Cannot write session to /tmp/vufind_sessions/sess_nalt526l38cmpo0i6vbr7anhd0